StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial

Company to Host Webcast to Discuss Interim Data Today

NEWARK, Calif., June 19, 2014 -- StemCells, Inc. (STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC^(R) human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12^th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.

Interim trial results show a 65 percent reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 percent reduction in the rate of GA when compared to the control eye.

Published: 19 June 2014

Written by Editor

Nasdaq Up on News Project Update

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial

- PBI-4050 well tolerated; no serious adverse events reported - PBI-4050 set to target orphan conditions in addition to diabetic patients with chronic kidney disease

LAVAL, QUEBEC- Jun 18, 2014 - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF), ("ProMetic" or the "Corporation") reported today that it has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers. ProMetic's PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested.

The objectives of this oral, double blind, placebo controlled, single ascending dose study were to demonstrate the safety and tolerability of PBI-4050 and to establish the pharmacokinetic profile of the drug candidate at different doses. The study design also included a component looking at food effect on drug absorption. The trial was conducted in 5 cohorts of 8 subjects. In each cohort, 6 subjects received PBI-4050 and 2 subjects received matching placebo.

Published: 18 June 2014

Written by Editor

TSX Up on News Project Update

EnteroMedics Announces FDA Advisory Committee Recommendation on VBLOC(R) Vagal Blocking Therapy for the Treatment of Obesity

Panel Votes 6 to 2, With 1 Abstention, That Benefits Outweigh Risks

ST. PAUL, MN--(Marketwired - Jun 17, 2014) - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) Advisory Gastroenterology and Urology Devices Panel (GUDP) voted 8 to 1 "in favor" that the device is safe when used as designed, and voted 4 to 5 "against" on the issue of a reasonable assurance of efficacy. The final vote, on whether the relative benefits outweighed the relative risk, was 6 to 2 "in favor," with 1 abstention.

Published: 18 June 2014

Written by Editor

Nasdaq FDA HC Decision Up on News Interesting News

Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers

PORTLAND, Ore., June 17, 2014 -- Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the completion of enrollment in the Company's Phase 2a clinical trial for GALE-301, or Folate Binding Protein (FBP) peptide immunotherapy. GALE-301 is administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, ovarian and endometrial cancer patients rendered disease-free after completing standard of care therapy.

Published: 17 June 2014

Written by Editor

Nasdaq Project Updates Up on News Cancer

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15
Yale researchers present the latest in vitro and in vivo results at Drug Discovery and Therapy 2014 World Congress

BOSTON, June 17, 2014 -- Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer.

Trx-1 is being developed for the treatment of ovarian cancer, particularly for its ability to kill chemo-resistant ovarian cancer stem cells. Novogen and CanTx plan to file an Investigational New Drug application (IND) with the FDA in early 2015 and to start a Phase 1 study by mid-2015.

Published: 17 June 2014

Written by Editor

Nasdaq Up on News Cancer Project Update

StemCells Inc ( STEM )

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial

ProMetic Life Sciences Inc ( PLI )

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial

EnteroMedics Inc ( ETRM )

EnteroMedics Announces FDA Advisory Committee Recommendation on VBLOC(R) Vagal Blocking Therapy for the Treatment of Obesity

Galena Biopharma Inc ( GALE )

Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers

Novogen Limited ( NVGN )

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells